FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Syndicate content

MRSA related Press Releases

Usage of Zyvox Has Flattened or Declined in the Major European Markets While Uptake of Cubicin and Tygacil Has Climbed Yea

Posted December 15, 2011

MRSA Infections are a Key Driver of Zyvox and Cubicin Usage, According to New Report from Arlington Medical Resources EXTON, Pa.--(BUSINESS WIRE)-- Arlington Medical Resources (AMR), a provider of Read more...

Fujifilm Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Nove

Posted October 25, 2011

Fujifilm Diosynth Biotechnologies and ContraFect Corporation announced today that they have signed a contract to support the process development and cGMP manufacture of CF-301, ContraFect’s Read more...

Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day on October 1

Posted September 28, 2011

Third annual event held to pay tribute to patients and families, issue call-to-action to eradicate healthcare-associated infection epidemicINDIANAPOLIS, Sept. 28, 2011 /PRNewswire/ -- As part of its Read more...

PURE Bioscience Presents PURE Hard Surface at American Correctional Association’s Annual Congress

Posted August 8, 2011

SDC-Based Disinfectant and Sanitizer Kills Bacteria and Viruses in 30 Seconds; Effective against MRSA and NDM-1 Positive Bacteria SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (NASDAQ: PURE), Read more...

Excelimmune Completes $10.5 Million Series B Financing

Posted May 31, 2011

WOBURN, Mass.--(BUSINESS WIRE)-- Excelimmune, Inc. today announced the final closing of a $10.5 million Series B financing. Proceeds from the Series B will enable Excelimmune to advance Staphguard, a Read more...

Furiex Acquires Full Exclusive License Rights to Develop and Commercialize JNJ-Q2 (fluoroquinolone)

Posted April 19, 2011

MORRISVILLE, N.C.--(BUSINESS WIRE)-- Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 Read more...

Cubist Pharmaceuticals Revises 2010 Net Revenue Guidance

Posted December 14, 2010

- Total Net Revenue 2010 Guidance revised to a range of $634 Million to $640 Million - U.S. Net Product Revenue Guidance revised to a range of $598 Million to $605 Million LEXINGTON, Mass.--(BUSINESS Read more...

PRESS RELEASE: Scientists Identify Factor Key to Severity of Community-Associated Methicillin-Resistant Staph Infections

Posted November 13, 2007

Scientists Identify Factor Key to Severity of Community-Associated Methicillin-Resistant Staph Infections Newly described proteins in drug-resistant strains of the Staphylococcus aureus bacterium Read more...

PRESS RELEASE: CDC estimates 94,000 invasive drug-resistant staph infections occurred in the U.S. in 2005

Posted October 17, 2007

CDC estimates 94,000 invasive drug-resistant staph infections occurred in the U.S. in 2005 Study establishes baseline for MRSA infection estimates Methicillin–resistant staph aureus (MRSA) caused Read more...